We are live on ! Find out more
SCM

Sio Capital Management Portfolio holdings

AUM $697M
1-Year Est. Return 79.73%
This Fund
S&P 500
This Quarter Est. Return
+11.78%
1 Year Est. Return
+79.73%
3 Year Est. Return
+576.62%
5 Year Est. Return
+422.76%
10 Year Est. Return
+2,506.65%
AUM
$291M
AUM Growth
+$111M
Cap. Flow
+$101M
Cap. Flow %
34.52%
Top 10 Hldgs %
41.32%
Holding
85
New
36
Increased
17
Reduced
10
Closed
22

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$14.8M
2
BNGO icon
Bionano Genomics
BNGO
+$10.2M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$7.48M
4
UROV
Urovant Sciences Ltd.
UROV
+$6.99M
5
BIIB icon
Biogen
BIIB
+$6.64M

Top Sells

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$5.97M
2
ELV icon
Elevance Health
ELV
+$4.88M
3
ICLR icon
Icon
ICLR
+$4.61M
4
WTW icon
Willis Towers Watson
WTW
+$3.94M
5
RVTY icon
Revvity
RVTY
+$3.85M

Sector Composition

Rank Sector Weight
1 Healthcare 74.76%
2 Financials 4.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHG icon
26
Philips
PHG
$25.8B
$4.36M 1.5%
123,389
-7,686
-6% -$263K
AMGN icon
27
CALL
Amgen
AMGN
$209B
$4.15M 1.42%
+20,000
New +$3.94M
RVNC
28
DELISTED
Revance Therapeutics, Inc.
RVNC
$4.08M 1.4%
164,353
+63,061
+62% +$1.72M
VKTX icon
29
Viking Therapeutics
VKTX
$3.86B
$3.71M 1.27%
213,252
-68,052
-24% -$810K
ALXN
30
DELISTED
Alexion Pharmaceuticals
ALXN
$3.58M 1.23%
+25,785
New +$3.23M
ICLR icon
31
Icon
ICLR
$12.8B
$3.57M 1.22%
23,198
-32,134
-58% -$4.61M
STRO icon
32
Sutro Biopharma
STRO
$411M
$3.49M 1.2%
+23,254
New +$3.51M
MDT icon
33
Medtronic
MDT
$110B
$3.46M 1.19%
+35,196
New +$3.25M
AZN icon
34
PUT
AstraZeneca
AZN
$266B
$3.46M 1.19%
+43,700
New +$3.31M
CAH icon
35
Cardinal Health
CAH
$53.2B
$3.35M 1.15%
62,004
-64,766
-51% -$3.31M
UNH icon
36
UnitedHealth
UNH
$383B
$3.35M 1.15%
12,579
+1,414
+13% +$368K
AGN
37
PUT
DELISTED
Allergan plc
AGN
$3.33M 1.14%
+17,500
New +$3.21M
PFE icon
38
PUT
Pfizer
PFE
$142B
$3.15M 1.08%
75,361
-30,039
-29% -$1.16M
EBS icon
39
Emergent Biosolutions
EBS
$375M
$2.75M 0.94%
+41,799
New +$2.44M
NVRO
40
DELISTED
NEVRO CORP.
NVRO
$2.57M 0.88%
+45,091
New +$2.82M
VTAK icon
41
Catheter Precision
VTAK
$1M
$2.47M 0.85%
+1
New +$4.54M
AFMD
42
DELISTED
Affimed
AFMD
$2.43M 0.83%
+55,762
New +$1.58M
HRC
43
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$2.27M 0.78%
24,036
+2,587
+12% +$243K
ARWR icon
44
Arrowhead Research
ARWR
$12.3B
$2.19M 0.75%
+114,259
New +$1.88M
CFMS
45
DELISTED
Conformis, Inc. Common Stock
CFMS
$1.97M 0.68%
74,472
+8,691
+13% +$236K
SENS icon
46
Senseonics Holdings Inc
SENS
$265M
$1.92M 0.66%
+20,120
New +$1.65M
FRTX
47
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$1.7M 0.58%
+3,936
New +$1.66M
ABUS icon
48
Arbutus Biopharma
ABUS
$871M
$1.56M 0.53%
+164,943
New +$1.64M
AKCA
49
PUT
DELISTED
Akcea Therapeutics Inc
AKCA
$1.52M 0.52%
+43,300
New +$1.31M
PBYI icon
50
Puma Biotechnology
PBYI
$402M
$1.5M 0.52%
+32,832
New +$1.58M
1
2
3 4

Similar funds

GUB
Golden Unicorn BVI Road Town $697M AUM 55.92% 1-Year Est. Return
KLI
Kelman-Lazarov Inc Memphis, Tennessee $698M AUM 14.07% 1-Year Est. Return
JA
JLB & Associates Plymouth, Michigan $696M AUM 17.86% 1-Year Est. Return
WIC
Wilkins Investment Counsel Boston, Massachusetts $698M AUM 17.36% 1-Year Est. Return
AAM
Auxier Asset Management Aurora, Oregon $696M AUM 18.07% 1-Year Est. Return
TCM
Tensile Capital Management Larkspur, California $698M AUM 2.4% 1-Year Est. Return
CA
Calton & Associates Tampa, Florida $696M AUM 18.3% 1-Year Est. Return
SAM
Silverback Asset Management Chapel Hill, North Carolina $699M AUM 72.42% 1-Year Est. Return

Sio Capital Management's Q3 2018 Portfolio in Review

As of Q3 2018, Sio Capital Management held 85 positions worth $291M, up 61% from $181M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Sio Capital Management deployed $101M of net new capital in Q3 2018, opening 36 new positions and adding to 17 existing holdings. Its largest new stake was GSK: 291,168 shares worth $14.6M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 80% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Elevance Health, an estimated $4.88M trimmed.

  • Sio Capital Management's largest Q3 2018 buy was GSK: 291,168 shares worth $14.6M.
  • Sio Capital Management added most to Alnylam Pharmaceuticals in Q3 2018, an estimated $7.48M increase.
  • Sio Capital Management's biggest Q3 2018 reduction was Elevance Health, cutting an estimated $4.88M.
  • Sio Capital Management fully exited Boston Scientific in Q3 2018, selling an estimated $5.97M.
  • Sio Capital Management's ten largest holdings make up 41% of its $291M portfolio in Q3 2018.
  • Sio Capital Management opened 36 new positions and closed 22 in Q3 2018.
  • Sio Capital Management's portfolio value rose 61% quarter-over-quarter to $291M.

Based on Sio Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.